An Israeli woman receives a Pfizer-BioNtech Covid-19 vaccine on Feb. 7, 2021, in Hadera. Photo by Gili Yaari/Flash90
by Abigail Klein Leichman
(Israel21c) — People who’ve received the Pfizer-BioNTech vaccination against Covid-19 seem significantly less likely to “shed” or transmit virus particles that may be in their nose or throat.
That is the finding of a study pre-published on Feb. 8 by Israeli scientists from Covid testing centers MyHeritage Lab and the Central Virology Laboratory at Sheba Medical Center.
The study, whose results have not yet been peer reviewed, may answer the key question of whether Covid-19 vaccines not only protect the vaccinee but also people in proximity to the vaccinee.
Such a study was possible only because real-world data is abundant in Israel, which started its Pfizer vaccination rollout on Dec. 20 and focused on individuals 60 and older.
“By now, more than 75 percent of the individuals of this age group have been at least 14 days after the first dose, compared to 25 percent of the individuals between ages 40-60 years old,” the researchers noted.
The study traced the cycle threshold (Ct) value distribution — which indicates how much virus an infected person harbors — of 16,297 positive qPCR tests performed between Dec. 1 and Jan. 31 from these two age groups.
“As we do not have access to the vaccine status of each test, our hypothesis was that if vaccines reduce viral load, we should see a difference in the Ct values between these two age groups in late January but not before,” they explained.
Sure enough, until Jan. 15 there was no statistically significant difference in the average Ct value between the groups. In the last two weeks of January, as predicted, the average Ct value of 60+ individuals tested was significantly weaker compared to the younger group.
After corroborating these results using a mathematical model, the scientists used demographic data and daily vaccination rates to estimate the effect of vaccination on viral load reduction.
“Our estimate suggests that vaccination reduces the viral load by 1.6x to 20x in individuals who are positive for SARS-CoV-2. This estimate might improve after more individuals receive the second dose,” they wrote.
“Taken together, our findings indicate vaccination is not only important for individual’s protection but can reduce transmission.”
The study’s authors are Prof. Yaniv Erlich, chief science officer of MyHeritage; Ella Petter, Danit Oz-Levi, and Asaf Younger of MyHeritage; Orna Mor and Neta Zuckerman of the Central Virology Lab; and Dvir Aran of the Technion-Israel Institute of Technology.